



March 29, 2024

To,

BSE Limited
The Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Ltd
Listing Department, Exchange Plaza,
5th Floor, Plot No C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400 051

Scrip Code : 520113

Scrip Code : VESUVIUS

Dear Sirs/Madam,

Sub: Newspaper Notice to the Shareholders for 33rd Annual General Meeting of the Company

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of the advertisement of Notice dated March 27, 2024 published on March 28, 2024 in Business Standard (in English) and Aajkaal (in Bengali) both also having electronic editions, for the 33rd Annual General Meeting of the Company, scheduled to be held on Thursday, April 18, 2024 at 10.00 A.M. (IST) at G. D. Birla Sabhagar, 29, Ashutosh Chowdhury Avenue, Kolkata – 700 019.

The aforesaid information is also available on the website of the Company, viz., www.vesuviusindia.in.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For **Vesuvius India Limited**



Saheb Ali

Company Secretary and Compliance Officer

Membership No. A33361

Encl.: As above

Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

SOHINI DAS
Mumbai, 27 March

Mumbai-based Cipla is evaluating acquisition in areas such as oncology, mental health, obesity, wellness, genomics, and diagnostic services, Umang Vohra, managing director and global chief executive officer, told *Business Standard*.

After tying up with Sanofi India on Tuesday to distribute its (Sanofi's) central nervous system (CNS) products in the country, Cipla is open to licensing and collaboration deals with multinationals in the anti-diabetes space.

Tuesday's deal is to distribute Sanofi India's six CNS brands, including Frisium, a leading product in the anti-epileptic medication category.



BIG PLANS AHEAD

- Firm looking for acquisition opportunities in oncology, mental health, obesity, wellness, genomics and diagnostic services
- Also eyeing licensing opportunities and collaborations with global multinationals in the diabetes space
- Had net cash balance of ₹7,143 crore as of Dec 2023

Analysts say as Cipla aims to move from being a pharma company to being an integrated health care player, it is evaluating opportunities in these areas. In a recent analysis, Nuvama Institutional Equities noted that while Cipla was not a top player in the CNS and diabetes segments in India, it aimed to grow in these chronic-disease therapies.

A focus on these areas is understandable because India is projected to have over 134 million diabetics by 2045 while cancer cases are expected to increase 12 per cent by 2025.

Obesity is expected to affect over 5 per cent of India's adult population by 2025.

The company has a net cash balance of ₹7,143 crore as of December 2023. It has an overall cash balance of ₹7,591 crore, including cash and cash equivalents.

Nuvama analysts in a report said: "It is increasingly engaging with start-up ecosystems to invest in different areas of oncology, obesity, mental health, wellness, genomics, Diagnostic services, etc. The company sees significant growth opportunities and is thinking beyond the pill by working on various aspects i.e. pill, nutrition, clinics and digital. This is likely to provide a leg up to its consumer health business."

Cipla has been beating domestic formulations consistently by 100-200 basis points in market growth. Nuvama analysts said in March Cipla could continue to outperform the Indian pharma market (IPM) and reach second spot.

The company's last 12 months' turnover (also called moving annual turnover) has clocked a 9.7 per cent growth rate as of February 2024,

according to the IQVIA and Nuvama data. Cipla is strong in the respiratory segment. Its respiratory product, Foracort, recently touched a ₹100 crore per month run rate and comes on top in the prescription market.

Cipla's growth in anti-diabetics (7.8 per cent) has picked up in the past three months.

"Due to its focus on the chronic therapies, Ebidta (earnings before interest, tax, depreciation, and amortisation) margins in the domestic business are likely to improve," Nuvama added.

Chronic medicines are ringing up a steady growth rate even in small towns, driven by increased health care awareness, more private-sector investment, and government support.

Non-communicable diseases are responsible for around 63 per cent of deaths in India.

Pharma firms bank on 'mother brands' to boost growth

Pharma companies are focussing on flagship products or mother brands, under which they launch various new combinations, to ensure robust revenue growth as well as therapy leadership.

An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales.

"Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success," says Sheetal Sapale, vice-president, commercial, Pharmarack.

She added that pharma companies are using flagship brands to develop strong therapy connections, move from low priced acute therapy to more premium priced chronic or sub-chronic therapy versions, and also using this as a launch pad for combinations with molecules going off-patent.

"Despite the introduction of multiple line extensions, Telma remains the strongest brand under the umbrella. Strong brand identity for the treatment of hypertension has supported success in the launch of multiple brands with the enhancement of Telmisartan with newer molecules for better management of hypertension. While Telma stays strong in its molecular market, the other brands in the family also enjoy a formidable market share," Sapale said.

COMPILED BY SOHINI DAS



GOING STRONG

Mother brands have shown robust growth in past 5 years

Mother brand	MAT sales Feb 2024 (₹ cr)	5-Year CAGR (in %)
Zerodol	1,005	20
Rosuvvas	752	20
Manforce	705	26
Dexolac	547	27
Unwanted	459	19
Prega News	303	33
Tresiba	270	39
Novo Germina	233	80
Neosporin	230	19

Number of mother brands above ₹200 cr

Therapy segment	Mother brands
Cardiac	22
Anti-infectives	19
Gastro-intestinal	20
Anti-diabetic	20
Vitamins	12
Pain/analgesics	10
Respiratory	20

MAT: Moving annual turnover
Source: PharmaTrac MAT Feb 2024

DRL to distribute Sanofi's vaccines

Dr Reddy's Laboratories Limited (DRL) has entered into an exclusive distribution partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across private markets in the country.

The pact is aimed at expanding the availability of Sanofi's vaccine brands, both paediatric and adult, within private markets in India.

It comes a day after Sanofi India announced a separate partnership with Cipla to

boost access to Sanofi's Central Nervous System (CNS) medications across India. Under the terms of the agreement, DRL will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetrixim, Menaetra, FluQuadri, Adacel, and Avaxim 80U. These brands have collectively generated approximately ₹426 crore in sales as of IQVIA MAT February 2024. Sanofi will continue to retain ownership,

manufacture, and import these brands into the country.

Speaking on the pact, Preeti Futnani, general manager India for vaccines at Sanofi, said: "Vaccine confidence has reached its highest in India in the last few years. Yet, there is much to be done for the rest of the country's large unvaccinated cohort. To expand our geographic reach, we're pleased to partner with Dr. Reddy for exclusive distribution and promotion."

ANJALI SINGH

Aim to double our size by 2030, says IndiGo CEO

PRESS TRUST OF INDIA
New Delhi, 27 March

IndiGo aims to double in size by 2030 with new domestic and international routes as well as destinations, its chief Pieter Elbers said as the airline pursues soaring global ambitions to match India's economic growth potential.



The country's largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet "somewhere in 2025", to further expand its overseas presence.

Seeking to consolidate as well as expand its position on the global scale, Elbers told *PTI* in an interview that the next big jump for IndiGo will be to double its size by the end of the decade.

GOING FORWARD, WE WILL BE SEEING A NUMBER OF NEW INTERNATIONAL DESTINATIONS. WE WILL HAVE SOME DOMESTIC BUT MORE IN INTERNATIONAL

PIETER ELBERS
CEO, IndiGo

For the next financial year starting April 2024, the IndiGo chief said the capacity guidance in terms of seat capacity is "early double digits" and one plane is coming in every week.

Amid supply chain as well as Pratt & Whitney engine woes, Elbers also emphasised that the airline is taking a lot of mitigating measures that are bearing fruits, and that the Aircraft on Ground (AOG) situation is "stable".

In February, the airline said the number of AOGs was in the mid-70s.

Currently, the 17-year-old carrier operates to 88 domestic and 33 international destinations. It has a fleet of more than 360 planes.

"An airline with double of today's size, global reach and footprint by the year 2030. That is the ambitious target..." Elbers said and added that more codeshare partnerships can be expected.

IndiGo plane brushes wings of A-1 Express; DGCA launches probe

An IndiGo aircraft grazed the wings of an Air India Express plane at the Kolkata airport on Wednesday, leaving wings of both aircraft damaged, officials said.

The Directorate General of Civil Aviation (DGCA) has launched a probe and de-registered two IndiGo pilots involved in the incident, a senior DGCA official said.

At present, IndiGo has codeshares with Turkish Airways, British Airways, Qatar Airways, American Airline, KLM-AirFrance, Qantas, Jetstar, and Virgin Atlantic.

Codesharing allows an airline to book its passengers on its partner carrier and provide seamless travel to various destinations.

"Clearly, going forward, we will be seeing a number of new international destinations. We will have some domestic but more international... I would say. Especially, the opportunity to have more international routes, not per se destinations only," he said and cited the example of services to Singapore that have been increased.

PI

VESUVIUS INDIA LIMITED
CIN: L26933WB1991PLC052968
Regd. Office: P-104, Taratala Road, Kolkata-700088
Phone: 033-61090500, Fax: 033-24013976
Email: vesuviusindia@vesuvius.com, Website: https://vesuviusindia.in

NOTICE OF 33rd ANNUAL GENERAL MEETING

NOTICE is hereby given that the 33rd Annual General Meeting ("AGM") of the Members of Vesuvius India Limited (the "Company") will be held on **Thursday, April 18, 2024 at 10:00 A.M. (IST)** at G. D. Birla Sabhagar, 29, Ashutosh Chowdhury Avenue, Kolkata – 700 019 to transact the businesses as set out in the Notice of the AGM dated February 9, 2024 (the "Notice").

The Annual Report for the financial year ended December 31, 2023 along with the Notice, Attendance Slip, Proxy Form and Route Map to the venue of the AGM, have been sent to the Members, electronically to those whose e-mail IDs are registered with the Company's RTA, Registrar and CB Management Services (P) Limited/Depository Participant(s) and have been dispatched by other permitted modes to those members who have not registered their e-mail IDs. The e-communication/dispatch have been completed on March 26, 2024. The Notice of the AGM and the Annual Report are available on the Company's website at www.vesuviusindia.in, as well as on its RTA's website www.cbmsl.com and on the website of the stock exchange(s) i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, and also on the website of National Securities Depository Limited ("NSDL") at www.evoting.nsdl.com.

Notice is also hereby given that the **Record Date** will be **Thursday, April 11, 2024** to determine those Members who will be entitled to receive dividend which will be declared at the AGM. Members are requested to kindly register/update their bank account details with the RTA/Depository Participant.

In terms of Section 108 of the Companies Act, 2013 (the "Act") read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI LODR"), and Secretarial Standard – 2, the Company is pleased to provide its Members facility of remote e-voting and Tab e-voting at the AGM through electronic voting services provided by NSDL. The Members are hereby informed that:

- The Ordinary and Special Businesses as set out in the Notice may be transacted through voting by electronic means;
- The remote e-voting shall commence from 9.00 a.m. (IST) on **Sunday, April 14, 2024** and ends at 5.00 p.m. (IST) on **Wednesday, April 17, 2024**;
- The Cut-Off date for determining the eligibility to vote by remote e-voting or Tab e-voting at the AGM, is **Thursday, April 11, 2024**;
- Any person who acquires shares of the Company and becomes a member of the Company after the dispatch of the Notice and holding shares as of the Cut-Off date, may obtain the User ID and Password by sending a request at evoting@nsdl.com or at ranarc@cbmsl.co. However, if Member is already registered with NSDL for e-voting then the existing User ID and Password can be used to cast vote. Any person who has ceased to be a Member of the Company as on the cut-off date will not be entitled for remote e-voting or voting at the AGM and should treat the Notice for information purpose only.
- Members are requested to note that:
 - remote e-voting module shall be disabled by NSDL and shall not be allowed after the aforesaid date and time for end of remote e-voting;
 - once the vote on a resolution is cast by the Member, the Member shall not be allowed to change its subsequently;
 - the facility for Tab e-voting will also be available at the AGM.
 - the Members who have cast their vote by remote e-voting may also attend the AGM but shall not be entitled to cast their vote again; and
 - a person whose name is recorded in the Register of Members or in the list of Beneficial Owners maintained by the depositories as on Cut-Off date only shall be entitled to avail the facility of remote e-voting as well as e-voting at the AGM.
- For e-voting instructions, (remote and Tab e-voting), Members may go through the e-voting instructions provided either through e-communication/the Notice. In case of any queries or issues connected with remote e-voting, Members may contact Ms. Pallavi Mhatre, at email id: evoting@nsdl.com or call at 022-4886 7000. In case of any queries, Members may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available in the download section of www.evoting.nsdl.com.
- The documents referred to in the Notice /Explanatory Statement are open for inspection in physical or in electronic form between 12.00 p.m. and 2.00 p.m. on all working days up to and including the date of the Annual General Meeting.

For Vesuvius India Limited
Sahab Ali
Date : March 27, 2024
Place: Kolkata
Company Secretary & Compliance Officer
Membership No.: A3361

NOTICE

Notice is hereby given that the following share certificate No (s) have been lost by me, which are standing in the name of **Aishwarya Mathukumilli** in the books of **M/s.Maharashtra Scooters Limited**, have been lost and the advertiser have applied to the company for issue of duplicate share certificate(s) in lieu thereof. Any person(s) who has /have claim(s) on the said shares should lodge such claim(s) with the Company's Registrars and Transfer Agents viz. Kfin Technologies Private Ltd, Selenium Tower – B, Plot No.31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 within 15 days from the date of this notice failing which the company will proceed to issue duplicate share certificate(s) in respect of the said shares.

Sl.No.	Folio No.	Share Cert. No.	No. of Shares	Distinctive Nos. From - To
1.	MSLSL0100150	4100	50	660506 - 660555
2.	MSLSL0100150	29578	21	1265288 - 1265288
3.	MSLSL0100150	46677	50	2303861 - 2303910
4.	MSLSL0100150	46678	21	2303911 - 2303931
5.	MSLSL0100150	116688	50	4343742 - 4343791
6.	MSLSL0100150	116689	50	4343792 - 4343841
7.	MSLSL0100150	116690	42	4343842 - 4343883
8.	MSLSL0100150	236587	50	8925278 - 8925327
9.	MSLSL0100150	236588	50	8925328 - 8925377
10.	MSLSL0100150	236589	50	8925378 - 8925427
11.	MSLSL0100150	236590	50	8925428 - 8925477
12.	MSLSL0100150	236591	50	8925478 - 8925527
13.	MSLSL0100150	236592	34	8925528 - 8925561
		Total	568	

Date: 27.03.2024
Place: Hyderabad

AISHWARYA MATHUKUMILLI
Name of the Shareholder(s)

NHPC Limited
(A Government of India Enterprise)

CIN: L40101HR1975GO032564
Regd. Off. : NHPC Office Complex, Sector-33, Faridabad-121003 (Haryana) India

NOTICE INVITING E-TENDER (PRESS NOTICE)

Tender Id 2024_NHPC_800202_1 Dated: 15.03.2024

Online Bids are invited by NHPC Limited Faridabad, India through **International Competitive Bidding in Single Stage -Two Part Bidding Basis** (i.e. Part-I: QR + Technical- Bid and Part-II: Financial Bid) from eligible bidders for **"Selection of RE Power Developers for Supply of 1200 MW Firm and Dispatchable power from ISTs connected Renewable Energy Power Projects coupled with energy storage system on 'anywhere in India' basis under Tariff Based Competitive Bidding (TBCB)-Tranche-II"**.

Complete NIT and Tender Documents can be downloaded and submitted through the portal <https://eprocure.gov.in/eprocure/app>. The site can also be viewed through e-procurement corner of NHPC website www.nhpcindia.com and CPP Portal. The last date of submission of online bids is **12.04.2024**. For further details, please visit <https://eprocure.gov.in/eprocure/app>. Bidders shall register themselves on the website to submit their bids. Subsequent amendments, if any, shall be posted only on the aforesaid websites, hence Bidders are advised to visit websites regularly.

Email: contcivil1-co@nhpc.nic.in **General Manager (CC-I)**

Invesco Mutual Fund

Invesco Asset Management (India) Pvt. Ltd.
(CIN: U67190MH2005PTC153471), 2101-A, 21st Floor, A Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai - 400 013

Telephone: +91 22 6731 0000, Fax: +91 22 2301 9422, Email: mfservices@invesco.com
www.invescomutualfund.com

CAUTIONARY NOTICE

Fake SEBI Registration Certificate in the name of Invesco Asset Management (India) Pvt. Ltd.

This is to caution the public that unknown person(s) have forged registration certificate as "stockbroker" in the name of Invesco Asset Management (India) Pvt. Ltd. ("IAMI") and is circulating on fake WhatsApp groups. Please note, IAMI is registered with SEBI only in the capacity as Asset Management Company under SEBI (Mutual Funds) Regulations, 1996 and Portfolio Manager under SEBI (Portfolio Managers) Regulations, 2020 and is not registered with SEBI in any other capacity.

Investors are hereby cautioned that these are fraudulent and deceptive social media group(s), and neither Invesco Mutual Fund, nor IAMI nor any of its executives are associated with such group(s) in any manner and shall not be held liable for any losses whatsoever suffered by any person who has / had relied on such unknown persons/fake social media groups.

For any information on our products/services, investors can visit our website at <https://invescomutualfund.com/> or contact IAMI officials at mfservices@invesco.com.

For Invesco Asset Management (India) Pvt. Ltd. (Investment Manager for Invesco Mutual Fund)

Sd/-
Saurabh Nanavati
Chief Executive Officer

Date: March 27, 2024

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

